journal
MENU ▼
Read by QxMD icon Read
search

CNS & Neurological Disorders Drug Targets

journal
https://www.readbyqxmd.com/read/29110629/commentary-endophenotypes-as-disease-modifiers-decoding-the-biology-of-alzheimer-s-by-genome-wide-association-studies
#1
A R Neelakandan, G K Rajanikant
No abstract text is available yet for this article.
November 6, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/29090671/targeted-blockade-of-tarp-g8-associated-ampa-receptors-anticonvulsant-activity-with-the-selective-antagonist-ly3130481-cerc-611
#2
Jeffrey M Witkin, Douglas A Schober, Scott D Gleason, John T Catlow, Warren J Porter, Jon Reel, X Jin, J Hobbs, Donald Gehlert, Douglas L Gernert, Kevin M Gardinier, Akihiko S Kato, X Ping, J L Smith
6-[(1S)-1-[1-[5-(2-hydroxyethoxy)-2-pyridyl]pyrazol-3-yl]ethyl]-3H-1,3-benzothiazol-2-one (LY3130481 or CERC-611) is a selective antagonist of AMPA receptors containing transmembrane AMPA receptor regulatory protein (TARP) g-8 that is under development for epilepsy. The present study provided a broad inquiry into its anticonvulsant properties. LY3130481 was anticonvulsant in multiple acute seizure provocation models in mice and rats. In addition, LY3130481 was effective against absence seizures in the GAERS genetic model and in the Frings mouse model...
November 1, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/29076437/book-review-dendrites-third-edition
#3
Gislaine Z Réus
No abstract text is available yet for this article.
October 27, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/29076436/low-dose-of-anisodine-hydrobromide-induced-neuroprotective-effects-in-chronic-cerebral-hypoperfusion-rats
#4
Dandan Chen, Xiaofang Xie, Qiuling Chen, Han Liu, Shiyang Zhang, Feng Wan, Hui Ao, Cheng Peng
BACKGROUND: Chronic cerebral hypoperfusion is a common pathophysiological state in various cerebrovascular diseases. Anisodine has been reported to exerts neuroprotective effects in cerebral ischemia/reperfusion(I/R) animal model. However, it is poorly understood whether anisodine hydrobromide, the hydrochloride format of anisodine, one of tropic alkanes alkaloids, processes the same neuroprotective effect on chronic cerebral hypoperfusion(CCH) rats. Herein, we designed a way to evaluate these issues...
October 26, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/29065845/identification-of-electrophysiological-changes-in-alzheimer-s-disease-a-microarray-based-transcriptomics-and-molecular-pathway-analysis-study
#5
Zeenat Mirza, Nisreen Rajeh
Involvement of amyloid beta and tau proteins in pathogenesis of Alzheimer's disease (AD) has been studied extensively. However, electrophysiological activity, and cellular processes like membrane transport are mostly unstudied. Electrophysiological processes provide a bridge between brain activity and cognition, and show promise as translatable biomarkers in preclinical and clinical applications. Biochemical imbalance leads to change in glutamate-based neurotransmission, antioxidant capacity, and in membrane polarization-repolarization events, eventually, resulting in AD...
October 23, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28982340/the-18-kda-translocator-protein-tspo-as-a-cns-drug-target-finding-our-way-through-the-neuroinflammation-fog
#6
Michaela D Filiou, Richard B Rabati, Manuel B Graeber
The 18-kDa translocator protein (TSPO) is located in the outer mitochondrial membrane where it is thought to co-regulate steroidogenesis, cellular bioenergetics as well as several other cellular processes. Originally discovered as a binding site for diazepam outside the CNS, notably in steroidogenic tissue and mononuclear phagocytes, the TSPO's historical designation was peripheral benzodiazepine receptor. Much of the recent interest in the TSPO is due to the observation that its regulation in the brain is associated with microglial activation...
October 4, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28969559/genetic-signatures-in-ischemic-stroke-focus-on-aspirin-resistance
#7
Anjana Munshi, Kanika Vasudeva, Pratibha Chaurasia, Sulena Singh
Stroke is one of the leading causes of death. There has been compelling evidence that stroke has a genetic component. Genetic variants not only influence susceptibility to stroke but have also been found to alter the response to pharmacological agents and influence the clinical outcome of the disease. Stroke patients are treated with antiplatelet drugs like aspirin and clopidogrel to prevent a secondary stroke. Inspite the fact that many new antiplatelet drugs have been developed; aspirin is still considered as a golden standard for the antiplatelet therapy...
October 2, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28933261/pharmacological-treatment-of-cognitive-symptoms-in-major-depressive-disorder
#8
Zihang Pan, Radu C Grovu, Danielle S Cha, Nicole E Carmona, Mehala Subramaniapillai, Margarita Shekotikhina, Carola Rong, Yena Lee, Roger S McIntyre
: Background: Cognitive dysfunction is a core transdiagnostic domain of Major Depressive Disorder (MDD) and is a principal determinant of functional recovery. However, it has been insufficiently targeted within the current therapeutic framework for MDD. OBJECTIVE: To highlight these unmet cognitive needs in MDD. METHODS: An article search was conducted using PubMed from inception to November 2016: Major Depressive Disorder (and/or variant) was cross-referenced with the following terms: antidepressants, augmentation, cognition, cognitive deficits, cognitive dysfunction, functional outcomes, mechanism of action, and treatment...
September 18, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28933260/older-and-newer-strategies-for-the-pharmacological-treatment-of-agitation-in-schizophrenia-and-bipolar-disorder
#9
Giovanni Amodeo, Andrea Fagiolini, Gabriele Sachs, Andreas Erfurth
BACKGROUND: Treatment of acute agitation in patients with bipolar disorder and schizophrenia is a multifaceted and dynamic task, which presents unique and complex challenges to healthcare providers. OBJECTIVE: To ascertain and describe which medications are best to use in agitated patients with schizophrenia or bipolar disorder Method: Selective review of current guidelines and of the literature pertaining to the treatment of agitation in patients with schizophrenia or bipolar disorder Results: Pharmacologic treatment of agitation should be based on an assessment of the most likely cause of the agitation...
September 18, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28799490/neurotransplantation-therapy-and-cerebellar-reserve
#10
Jan Cendelin, Hiroshi Mitoma, Mario Manto
Neurotransplantation has been recently the focus of interest as a promising therapy to substitute lost cerebellar neurons and improve cerebellar ataxias. However, since cell differentiation and synaptic formation are required to obtain a functional circuitry, highly integrated reproduction of cerebellar anatomy is not a simple process. Rather than a genuine replacement, recent studies have shown that grafted cells rescue surviving cells from neurodegeneration by exerting trophic effects, supporting mitochondrial function, modulating neuroinflammation, stimulating endogenous regenerative processes, and facilitating cerebellar compensatory properties thanks to neural plasticity...
August 10, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28782488/microrna-dysregulation-in-alzheimer-s-disease
#11
Manish Putteeraj, Mohamad Fairuz Yahaya, Seong Lin Teoh
Alzheimer's disease (AD) is arguably the largest healthcare issue of our time. AD is thought to be principally the result of an inter-play between the β-amyloid peptide and Tau, and it is driven by several genetic and environmental risk factors. Recent studies have shown that small non-protein-coding microRNA (miRNA) and the associated post-transcriptional gene regulation are important regulators of many neurodegenerative diseases, including AD. We reviewed recent studies identifying various miRNA dysregulated in AD...
August 7, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28782487/natalizumab-changes-the-peripheral-profile-of-the-th17-panel-in-ms-patients-new-mechanisms-of-action
#12
Rodica Ioana Bălașa, Simu Mihaela, Septimiu Voidăzan, Laura Iulia Bărcuțean, Zoltan Bajko, Adina Huțanu, Iunius Simu, Smaranda Maier
INTRODUCTION: Natalizumab (NAT) is an effective treatment for relapsing remitting multiple sclerosis (RRMS),as it makes the blood-brain-barrier impenetrable bybinding to the α4integrin subunit. The objectives of our study were to find new peripheral mechanisms of action of NAT and new biomarkers of treatment response. MATERIAL AND METHODS: We prospectively assessed the serum levels of 15 cytokines from the Th17 Cytokine Panelusing Bio-plex Pro Human in a group of 29 RRMS patients treated with NAT and 29 healthy subjects(HS) at inclusion and after 8 months of NAT treatment...
August 7, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28782486/nf-kb-as-a-mediator-of-brain-inflammation-in-ad
#13
Jin Tae Hong
Alzheimer's disease is the most common form of dementia. It is characterized by beta-amyloid peptide fibrils which are extracellular deposition of a specific protein, and is accompanied by extensive neuroinflammation. Various studies show the presence of a number of inflammation markers in the AD brain: elevated inflammatory cytokines and chemokines, and an accumulation of activated microglia in the damaged regions. NF-kB is a redox of transcriptional factors, and it is known to be located in the genes involved in amyloidogenesis and inflammation...
August 7, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28782490/unmet-needs-in-schizophrenia
#14
Maurizio Pompili, Gloria Giordano, Mario Luciano, Dorian A. Lamis, Valeria Del Vecchio, Gianluca Serafini, Gaia Sampogna, Denise Erbuto, Peter Falkai, Andrea Fiorillo
The objectives of this article are to describe current trends in the treatment of schizophrenia and the most interesting new approaches to optimizing outcome and fostering the development of new schizophrenia treatments. RESULTS: Increasing utilization of diverse types of atypical antipsychotic drugs (AAPDs), e.g. clozapine-type serotonin (5-HT)2A and weak dopamine (DA) D2 antagonist, amisulpride, a D2/D3/5-HT7 antagonist, and cariprazine, a D3 partial agonist with additional neurotransmitter targets, is occurring as their advantages in efficacy, especially for cognitive impairment and mood symptoms, and side effects is becoming appreciated...
August 3, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28782489/neural-correlates-in-patients-with-major-affective-disorders-an-fmri-study
#15
Gianluca Serafini, Maurizio Pompili, Andrea Romano, Denise Erbuto, Dorian A. Lamis, Marta Moraschi, Camilla Rossi-Espagnet, Mario Amore, Paolo Girardi, Alessandro Bozzao
Brain areas of functional activation during emotional stimuli and their correlations with affective temperaments evaluated using Temperament Evaluation of Memphis, Pisa, Paris and San Diego (TEMPS-A) and hopelessness levels assessed with Beck Hopelessness Scale (BHS) have been investigated. Brain activity in response to emotional stimuli was examined by Nuclear Magnetic Resonance Blood Oxygen Level Dependent (NMR BOLD) signal. Seventeen subjects (mean age ± SD = 57 ± 12), diagnosed with major affective disorders and eighteen healthy controls (HC) (mean age ± SD = 50±11) participated in this study...
August 3, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28758584/antidepressant-potential-of-peptides-new-insights-as-future-therapeutic
#16
Haroon Khan, Sumaira Khattak, Mohammad S Mubarak, Saud S Bawazeer, Tareq Abu-Izneid, Mohammad A Kamal
The clinical depression is an unsatisfactory mood disorder affecting millions of people worldwide. The disorder is associated with a phenomenal number of suicidal attempts each year and it has been estimated 10-20 million people around the world made in an attempt of suicide in some stage of the disease. Thus, medicinal intervention is ultimately required to avoid such type of extreme outcomes. There are numerous therapeutic antidepressant options in clinical practice, however, most of them face the challenge of efficacy, side effects and patient compliance...
July 31, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28758581/implications-of-pegylation-of-carbon-nanotubes-for-central-nervous-system-bioavailability
#17
Gisele Eva Bruch, Marcos F Cordeiro, Livia S Gomides, Carolina Peixoto, Arthur P Cordeiro, Lidiane Dal Bosco, Adelina P Santos, Daniela M Barros
In this mini-review we have compiled the most recent and comparable information to shed a light on the action of PEGylation in the biodistribution of Carbon Nanotubes (CNT) in the Central Nervous System (CNS). It is well known that due to the complexity of the CNS and the severity of the outcome of changes in this system, this is one of the areas where there are more investments in research to develop new technologies and approaches for more effective and less invasive treatments. The CNS is highly protected against toxic and invasive microorganisms thanks to the blood brain barrier (BBB), but this protection also prevents the passage of potentially beneficial molecules for the treatment of neurological disorders, Nanotechnology attempts to develop nanocompounds that are biocompatible and non-immunogenic, and that are able to cross the BBB in therapeutic amounts without causing damage and to diffuse through nerve tissue...
July 31, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28758580/chromosomal-micro-aberration-in-a-saudi-family-with-juvenile-myoclonic-epilepsy
#18
Muhammad Imran Naseer, Adeel G Chaudhary, Sameera Sogaty, Mahmood Rasool, Sajjad Karim, Hans-Juergen Schulten, Fehmida Bibi, Peter Natesan Pushparaj, Hussein A Algahtani, Mohammad H Al-Qahtani
Epilepsy is genetically complex neurological disorder affecting millions of people of the world. Juvenile myoclonic epilepsy (JME) is a most common epilepsy syndromes that starts in the teen age group commonly between ages 12 and 18, and lasts into adulthood. Out of 14 people with epilepsy one suffer with JME. Myoclonic seizures and muscle twitching or uncontrolled jerking are the most common type of seizure in the people suffering with JME. To observe the novel CNVs involved in JME we investigated a Saudi family with nine siblings with one male and one female affected members...
July 31, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28758583/new-trends-in-the-treatment-of-schizophrenia
#19
Herbert Y Meltzer
The objectives of this article are to describe current trends in the treatment of schizophrenia and the most interesting new approaches to optimizing outcome and fostering the development of new schizophrenia treatments. RESULTS: Increasing utilization of diverse types of atypical antipsychotic drugs (AAPDs), e.g. clozapine-type serotonin (5-HT)2A and weak dopamine (DA) D2 antagonist, amisulpride, a D2/D3/5-HT7 antagonist, and cariprazine, a D3 partial agonist with additional neurotransmitter targets, is occurring as their advantages in efficacy, especially for cognitive impairment and mood symptoms, and side effects is becoming appreciated...
July 28, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28758582/potential-novel-treatments-for-bipolar-depression-ketamine-fatty-acids-anti-inflammatory-agents-and-probiotics
#20
G H Vázquez, S Camino, L Tondo, Ross J Baldessarini
BACKGROUND: Treatments for depression in bipolar disorder (BD) are far less well developed than for unipolar major depressive disorder. Several innovative and experimental approaches have been emerging recently, including use of the dissociative anesthetic ketamine and other antagonists of central NMDA glutamate receptors, as well as unsaturated fatty acids, anti-inflammatory agents, and possibly probiotic methods. METHODS: We reviewed relevant reports from the past decade...
July 28, 2017: CNS & Neurological Disorders Drug Targets
journal
journal
41296
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"